الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 152 |  |  |
| | | from | 152 | | |
Abstract
More than 90% of all primary liver tumors are hepatocellular carcinomas (HCCs), the most prevalent kind of primary liver tumor. Currently the most common cause of death for those with cirrhosis, HCC affects about 85% of patients diagnosed with the disease. Fibrosis and cirrhosis, which arise in the context of chronic liver injury and inflammation, are linked to the development of HCC. Currently, the fifth most prevalent cause of cancer globally is hepatocellular carcinoma. HCC is the second most common cause of cancer-related mortality in men, after lung cancer. HCC has an 18% five-year survival rate, second only to pancreatic cancer. Early detection can result in successful treatment with surgery or a liver transplant, despite the fact that it can be fatal. Additional therapies reduce symptoms and lengthen the patient’s life.
Cartilage oligomeric matrix protein (COMP) is the fifth extracellular matrix glycoprotein member of the thrombospondin family. It is mostly expressed in cartilage, although it is also present in other tissues, including the cirrhotic liver and HCC. Its main job is to bind type I and type II collagen fibers. It has been suggested that COMP is a biomarker for fibrosis related to colon cancer in systemic sclerosis as well as harm to the skin, lungs, liver, and joints. Furthermore, COMP may function as a tumor-promoting agent in a number of cancers, including ovarian, parotid gland, and hepatocellular carcinoma.
Our study comprised 52 HCC patients with different stages, grade, tumor size and sub-sites from Minia Oncology Center. 121 patients in different stages of liver fibrosis are included in the current study. This study included 130 males and 43 females. Liver biopsy was performed for all 173 patients to identify degree of liver fibrosis. According to the METAVIR scoring-system, the fibrosis stage was F0 in 22 patients, F1 in 11, F2 in 21, F3 in 23, F4 in 44 patients and HCC in 52 patients. Accordingly, non-significant fibrosis (F0-F1) was identified in 33 samples (20 males & 13 females) and significant fibrosis (F2-F4) was 88 samples (66 males & 22 females). The result showed that there was very highly significant increased (p< 0.0001) in ALT, AST and ALP in group F4. It was discovered that HCC patients’ serum levels of COMP were significantly higher (p < 0.0001) than in the significant liver fibrosis patients (F2, F3), non-significant liver fibrosis (F0-F1) control group and cirrhotic liver patients (F4).
Conclusion
Our findings suggest that the COMP biomarker could help improve liver cancer laboratory diagnosis and may be a potential target for therapy monitoring. Further studies prospective, multicenter studies are needed to validate the results and confirm whether developed index can be used for accurate liver cancer diagnosis.